Are excellent systematic reviews of clinical trials useful for patient care?

Nature Clinical Practice Rheumatology

Volumn 4, Issue 6, 2008, Pages 294-295

  Pincus, Theodore ^a   Yazici, Yusuf ^a   Sokka, Tuulikki ^b  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFORMATION; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REVIEW LITERATURE AS TOPIC;

EID: 44849143594     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0812     Document Type: Review

References (16)

1. Donahue KE et al. (2008) Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148: 124-134
2. Feinstein AR (1983) An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 99: 544-550
3. Pincus T and Sokka T (2004) Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am 30: 701-724
4. Felson DT et al. (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33: 1449-1461
5. Pincus T et al. (1992) Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 19: 1885-1894
6. Yazici Y et al. (2005) Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64: 207-211
7. Sokka T and Pincus T (2003) Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 30: 1138-1146
8. Pincus T et al. (2005) Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 52: 1009-1019
9. Duclos M et al. (2006) Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33: 2433-2438
10. Sokka T et al. (2008) Treatment of rheumatoid arthritis. A global perspective of the use of antirheumatic drugs. Mod Rheumatol, in press
11. Puolakka K et al. (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum 52: 36-41
12. Grigor C et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 364: 263-269
13. Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 52: 3381-3390
14. Verstappen SMM et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449
15. Wolfe F and Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy. Arthritis Rheum 56: 2135-2142
16. Smith GC and Pell JP (2003) Parachute use to prevent death and major trauma related to gravitational challenge: Systemic review of randomised controlled trials. BMJ 327: 1459-1461